bortezomib

{
  "id": "MLC-T-ONC-001183",
  "term": "bortezomib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with multiple myeloma or mantle cell lymphoma. It is also being studied in the treatment of other types of cancer. Bortezomib blocks the action of enzymes called proteasomes, which may help keep cancer cells from growing and may kill them. It is a type of proteasome inhibitor. Also called PS-341 and Velcade.",
    "A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy."
  ],
  "synonyms": [
    "PS-341",
    "Velcade"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/bortezomib/"
}